No Picture
News

Anpac Bio Appoints Nobel Prize Winner Dr. Michael Levitt As Chief Consultant To Lead Anpac’s Pioneering Efforts In Cancer Screening

SAN JOSE, Calif., Dec. 11, 2019 /PRNewswire/ — Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today the appointment of Professor Michael Levitt of Stanford University to be the Chief Consultant of Anpac Bio’s Innovatio… […]

No Picture
News

BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update

SAN JOSE, Calif., Dec. 10, 2019 /PRNewswire/ — BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter en… […]

No Picture
News

Verantos Receives a Grant from the National Institutes of Health (NIH) to Fund Advanced Clinical Phenotyping in Real World Evidence Studies

PALO ALTO, Calif., Dec. 10, 2019 /PRNewswire/ — Verantos, the market leader in regulatory-grade real world evidence (RWE) studies, today announced that it has received a grant from the National Institutes of Health (NIH), National Center for Advan… […]

No Picture
News

An Agency of the U.S. Federal Government Selects Cloud-based ValGenesis VLMS to Digitalize Their Validation Lifecycle Processes

SAN FRANCISCO, Dec. 10, 2019 /PRNewswire/ — ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that an Agency of the U.S. Federal Government has chosen ValGenesis’s cloud-based, 100% p… […]

No Picture
News

Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma

– Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab — 48% Overall Response Rate Observed in Cerdulatinib Only; 76% Overall Response Rate Observed with Cerdulatinib in Combination with Rituximab –

SOUTH SA… […]

No Picture
News

Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting

SAN FRANCISCO, Dec. 9, 2019 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced three presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition for its IL-15 agonist and investigational candidate, … […]

No Picture
News

IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

– Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation- Pharmacokinetic Phase 1 clinical sub-study with immediate release… […]